active
ACTIVE SINCE: 2018

Gestational Diabetes in Mexico

Develop a screening algorithm and treatment protocol for women with gestational diabetes for primary care clinics to decrease maternal-child mortality rates and complications at birth.
SGDS CONTRIBUTING TO:
MEMBER COMPANIES:
Academia or research institute 1
Private Foundation or Development Organization 1

Lilly is collaborating with the Carlos Slim Foundation and the Mexican Society for Public Health on a five-year effort to improve outcomes for pregnant women with gestational diabetes and their babies. Through the collaboration, we are working to find a less expensive and better way to perform an oral glucose tolerance test to screen for gestational diabetes and help women who test positive avoid complications throughout their pregnancy. The partnership has delivered several important outcomes, including documenting the prevalence of gestational diabetes in Mexico (14%) for the first time at the national level, identifying three subtypes of the disease, and developing a simpler version of the oral glucose tolerance test. In 2022, more than 690,000 people benefited from the educational, diagnosis and improved care through this program.

Results and milestones

Partnership was launched in late 2018.

Geographic Reach
  • Americas
See Where
Disease Area
  • Non-communicable diseases
See Disease Areas
Target Population
  • Women
  • Children
SGDs the partnership contributes to
SDG 3: Good health and well-being
  1. 3.2: Reduce under-5 mortality 
  2. 3.4: NCDs (including mental health)
  3. 3.8: Achieve universal health coverage
SDG 5: Gender equality
SDG 17: Partnerships for the goals 
Partner organizations
Academia or research institute

Carlos Slim Health Institute

Private Foundation or Development Organization

Mexican Society for Public Health

Additional information